Holen Sie sich die Stockscreener-App
1.51
0.67%
0.01
Handel nachbörslich:
1.54
0.03
+1.99%
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World
Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma Inc. (IMMX) reports earnings - Quartz
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World
Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma
SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks
Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com
Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com
Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail
Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire
Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - The Globe and Mail
Immix Biopharma : Presentation (IMMX Corporate presentation February 2025) - Marketscreener.com
Is Qualcomm Stock a Buy Even Without Huawei Deal? - The Globe and Mail
Several Insiders Invested In Immix Biopharma Flagging Positive News - Yahoo Finance
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat
Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - Simply Wall St
FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World
HC Wainwright Predicts Weaker Earnings for Immix Biopharma - MarketBeat
Immix Biopharma Inc (IMMX-Q) QuotePress Release - The Globe and Mail
Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - The Manila Times
Immix Biopharma Completes Critical Phase 1b Safety Trial for Novel AL Amyloidosis CAR-T Therapy - StockTitan
Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial - Investing.com India
Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial By Investing.com - Investing.com South Africa
Immix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC Wainwright - MarketBeat
Immix Biopharma director Jason Hsu acquires shares worth $104,358 By Investing.com - Investing.com Canada
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - BioSpace
Immix Biopharma reports early success in CAR-T trial - Investing.com
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 - The Bakersfield Californian
Immix Biopharma (IMMX) Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - StreetInsider.com
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.5% in November - MarketBeat
Immix Biopharma reports promising CAR-T therapy results - Investing.com
Terex Corp (TEX-N) QuotePress Release - The Globe and Mail
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis - GlobeNewswire
Immix Bio's NXC-201 Achieves 75% Response Rate in AL Amyloidosis Trial, Clinical Data Published in JCO - StockTitan
Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis By Investing.com - Investing.com South Africa
Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis - Investing.com
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Immix Biopharma (IMMX) Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - StreetInsider.com
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):